Effect of Pioglitazone on Lipid Profile in Type 2 Diabetic Patients (original) (raw)
Muhammad Ahmad bilal
2012
visibility
…
description
7 pages
link
1 file
Effects of Pioglitazone on Visceral Fat Metabolic Activity in Impaired Glucose Tolerance or Type 2 Diabetes Mellitus
Toshi Abe
The Journal of Clinical Endocrinology & Metabolism, 2013
View PDFchevron_right
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes
Anders Grubb
Journal of Internal Medicine, 2006
View PDFchevron_right
Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study
Angel rodriguez
Cardiovascular Diabetology, 2011
View PDFchevron_right
Pioglitazone Treatment Enlarges Subcutaneous Adipocytes in Insulin-Resistant Patients
Fred C. G. J. Sweep
The Journal of Clinical Endocrinology & Metabolism, 2009
View PDFchevron_right
Pioglitazone reduces monocyte activation in type 2 diabetes
Simona Giubilato, Filippo Crea
2009
View PDFchevron_right
Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes
Supphamat Chirnaksorn
Cureus, 2021
View PDFchevron_right
Population Pharmacokinetics of Pioglitazone in South Indian Type-II Diabetic Patients
Devender Kodati
Asian Journal of Pharmaceutical and Clinical Research, 2014
View PDFchevron_right
Combined Therapy of Pioglitazone and Atorvastatin Alleviate Diabetes in Rats More Effectively than That of Mono Therapy
saiful Islam
Pharmacology & Pharmacy, 2014
View PDFchevron_right
Comparative evaluation of Pioglitazone versus Voglibose on glycemic control in patients with Type 2 Diabetes Mellitus on Metformin
Mohd Faheem Mubeen
Journal of Medical Science And clinical Research, 2018
View PDFchevron_right
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
Bancha Satirapoj
PLOS ONE, 2018
View PDFchevron_right
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.
Effect of metformin and Pioglitazone on insulin dose reduction in type 2 diabetes mellitus patients: An open level comparative prospective study
Anindya Dasgupta
Journal of Diabetes Mellitus, 2012
View PDFchevron_right
Pioglitazone provides beneficial effect in metabolic syndrome rats via affecting intracellular Na+ Dyshomeostasis
Belma TURAN
Journal of Bioenergetics and Biomembranes, 2018
View PDFchevron_right
Pioglitazone attenuates basal and postprandial insulin concentrations and blood pressure in the spontaneously hypertensive rat
Arthur Swislocki
American Journal of Hypertension, 2000
View PDFchevron_right
Lipoprotein profile characterization of the KKA(y) mouse, a rodent model of type II diabetes, before and after treatment with the insulin- sensitizing agent pioglitazone
Jerry Colca
Arteriosclerosis, Thrombosis, and Vascular Biology, 1993
View PDFchevron_right
The effect of pioglitazone on weight, lipid profile and liver enzymes in type 2 diabetic patients
farzad najafipour
Therapeutic Advances in Endocrinology and Metabolism, 2015
View PDFchevron_right
The effect of rosiglitazone on serum lipoprotein(a) levels in korean patients with type 2 diabetes mellitus
Bong-yun Cha
Metabolism, 2003
View PDFchevron_right
Comparisons of Rosiglitazone Versus Pioglitazone Monotherapy Introduction and Associated Health Care Utilization in Medicaid-Enrolled Patients with Type 2 Diabetes Mellitus
Roger Anderson
Clinical Therapeutics, 2007
View PDFchevron_right
Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis
Krassimir Kalinov
Diabetology & Metabolic Syndrome
View PDFchevron_right
Biochemical alterations and liver toxicity analysis with pioglitazone in healthy subjects
Md. Aftab Uddin
Drug and Chemical Toxicology, 2013
View PDFchevron_right
The effect of pioglitazone treatment on 15-epi-lipoxin A4 levels in patients with type 2 diabetes
somasekhar konduru
Atherosclerosis, 2012
View PDFchevron_right
Lipid profile of patients with diabetes mellitus: a cross sectional study
K. Uttra
International Journal of Research in Medical Sciences, 2015
View PDFchevron_right
Long-Term Lipid Effects of Pioglitazone by Baseline Anti-Hyperglycemia Medication Therapy and Statin Use from the PROactive Experience (PROactive 14)
Meng Tan
The American Journal of Cardiology, 2009
View PDFchevron_right
Antidiabetic Medications and Polypharmacy
Emily Peron
Clinics in Geriatric Medicine, 2015
View PDFchevron_right
Association of BMI, lipid lowering medication, and
Amelia Taylor Smith
View PDFchevron_right
A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus
Meng Tan
Clinical Therapeutics, 2003
View PDFchevron_right
Spotlight on Pioglitazone in Type 2 Diabetes Mellitus1
Dean Robinson, John Waugh
Treatments in Endocrinology, 2006
View PDFchevron_right
Studies on Lipid Profile Levels in Hypertensive and Type 2 Diabetes Mellitus
Benjamin Okolonkwo
American Journal of Biomedical and Life Sciences, 2014
View PDFchevron_right
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
Alfonso Pérez
Diabetes Care, 2005
View PDFchevron_right
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome
Frank Greenway
Diabetes, Obesity and Metabolism, 2009
View PDFchevron_right
Antihypertensive agents, serum lipoproteins and glucose metabolism
Johan Rosman
The American Journal of Cardiology, 1991
View PDFchevron_right
Medicine